Filter results

Hypersplenism clinical trials

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

View clinical trials related to Hypersplenism.

Filter by:

Not yet recruiting
Page 1

NCT ID: NCT03269877 Not yet recruiting - Hypersplenism Clinical Trials

Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension

Start date: September 1, 2017
Phase: N/A
Study type: Observational

The spleen could be considered a neglected organ. To date, it has been deemed an ancillary organ in portal hypertension or an organ localization in lymphoproliferative diseases. Hypersplenism is a common disorder characterized by an enlarged spleen which causes rapid and premature destruction of blood cells. It can result from any splenomegaly. It is most common with splenomegaly secondary to portal hypertension and hematological disorders. Portal Hypertension is an important cause of splenomegaly in most tropical countries This work will involve a series of studies aiming to: 1. Assess the prevalence and pattern of hypersplenism, and grade the severity of cytopenias in patients with cirrhosis and portal hypertension. 2. Elucidate the relationship between hypersplenism, in these patients, and: 1. The severity of liver cirrhosis as assessed by Child's and the Model of End-stage Liver Disease (MELD) scores. 2. The presence and grade of gastroesophageal varices as assessed by upper endoscopy. 3. The presence of hepatocellular carcinoma 4. Portal hemodynamics and portal vein thrombosis as assessed by Doppler Ultrasound. 3. Test the hypothesis that leucopenia in cirrhotic patients may be caused, at least in part, by apoptosis of polymorphnuclear leucocytes.